BETA
Your AI-Trained Oncology Knowledge Connection!
July 9th 2025
July 7th 2025
Luspatercept-aamt shows significant survival benefits and transfusion independence in lower-risk MDS, reshaping treatment standards in hematology.
July 2nd 2025
During a live event, Mojtaba Akhtari, MD, discussed trials studying patients with high-risk polycythemia vera.
June 23rd 2025
June 18th 2025
New findings reveal that combining erythropoiesis-stimulating agents with ruxolitinib maintains efficacy in treating myelofibrosis-related anemia.
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Asciminib Shows Better Tolerability in Newly Diagnosed CML-CP
Asciminib shows superior tolerability over nilotinib in newly diagnosed CML-CP patients, reducing treatment discontinuation due to adverse effects significantly.
Read More
Hematocrit Control, QOL Are Priorities in Low-Risk Polycythemia Vera
During a live event, Mojtaba Akhtari, MD, discussed the goals and treatment approach for patients with low-risk polycythemia vera.
JAK Inhibitor Selection Strategy: Risk-Guided Approach and Treatment Goals for Splenomegaly and Anemia
Panelists discuss how risk stratification, symptom burden, and splenomegaly guide treatment decisions for a 68-year-old woman with intermediate-risk myelofibrosis who isn’t interested in transplant.
Watch
Insights From VERIFY: Rusfertide Shows Promise in Polycythemia Vera
A groundbreaking study reveals rusfertide's potential to transform polycythemia vera treatment, reducing phlebotomy needs and improving patient quality of life.
The Future of Rusfertide Research in Polycthemia Vera
Rusfertide Shines as New Treatment Option in Polycythemia Vera
In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a potential new therapy in the space.
Luspatercept Shows Durable RBC-TI in Lower-Risk MDS Patients
Luspatercept significantly improved red blood cell transfusion independence duration and overall survival in ESA-naive, lower-risk MDS patients vs epoetin alfa.
Optimizing Anemia Care with Targeted Therapies for Low-Risk MDS
During a live event, Christopher Benton, MD, discussed treatment of myelodysplastic syndromes like luspatercept and imetelstat as alternatives to ESAs.
Optimizing JAK Inhibitor Use for Hemoglobin and Platelet Regulation in Myelofibrosis (Part 2)
In part 2, experts discuss optimizing the use of JAK inhibitors for patients with myelofibrosis.
Seiter Explores Time of Initiation and Alternate Dosing of Ruxolitinib in Myelofibrosis
During a live event, Karen Seiter, MD, discussed the role of the JAK/STAT pathway in myeloproliferative neoplasms and the use of ruxolitinib to treat myelofibrosis.
Quality-of-Life Improvement Is Highly Valued in Polycythemia Vera
Douglas A. Tremblay, MD, discusses the importance of quality-of-life data from treating patients with polycythemia vera with ropeginterferon alfa-2b-njft.
Fedratinib Shows Promise in Rare Myeloproliferative Neoplasms
Andrew Kuykendall, MD, discusses data from a phase 2 trial of fedratinib for the treatment of myeloproliferative neoplasms.
FDA Fast-Tracks Givinostat for Polycythemia Vera Treatment
The FDA granted fast track status to givinostat for treating high-risk polycythemia vera, supporting its potential shown in the ongoing phase 3 GIV-IN PV trial.
Starting Therapy for Intermediate-Risk Myelofibrosis Based on Hemoglobin
During a live event, Mark J. Fesler, MD, and participants discussed selection and timing of initiation of JAK inhibitor therapy for myelofibrosis.
Ropeginterferon Alfa Shows Disease-Modifying Potential in Polycythemia Vera
Douglas A. Tremblay, MD, discusses the data showing disease-modifying potential of ropeginterferon alfa-2b-njft in patients with polycythemia vera.
Assessing Risk for JAK Inhibitor Selection in Myelofibrosis
In part 1, experts explores how assessing individual risk factors is crucial in selecting the appropriate JAK inhibitor for patients with myelofibrosis.
Considering Therapy in a Patient With Myelofibrosis Eligible for Transplant
During a live event, Mark J. Fesler, MD, and participants discuss next steps for a 68-year-old patient with intermediate-risk myelofibrosis.
Elmariah on the Evolving Role of Fedratinib
Hany Elmariah, MD, discusses how he sees fedratinib fitting into clincal practice for the treatment of myeloproliferative neoplasms.
Bexmarilimab Shows Promise in Tough-to-Treat HR MDS; Phase 3 Planned
Bexmarilimab and azacitidine showed continued tolerability and a high overall response rate in relapsed/refractory higher-risk myelodysplastic syndromes in a phase 2 study.
Elmariah on Maintenance Therapy Post Transplant for Myelofibrosis Relapse and GVHD Prevention
Hany Elmariah, MD, discusses incorporating fedratinib as maintenance therapy in the posttransplant setting to prevent relapse of MPNs and graft-vs-host disease.
Fedratinib Shows Promise in Long-Term MPN Success With Tolerable Toxicity
Hany Elmariah, MD, discusses dose-limiting toxicities of fedratinib in a phase 1 study exploring the drug in patients with myeloproliferative neoplasms after HCT.
Addressing Treatment Gaps in High-Risk CML in Blast Phase
Akriti Jain, MD, discussed how emerging data on non-ABL1 mutations is reshaping chronic myeloid leukemia management.
Ropeginterferon Alfa Reduces JAK2 Allele Burden Over Long Term in PV
Douglas A. Tremblay, MD, discusses the long-term data supporting ropeginterferon alfa-2b-njft as treatment in patients with polycythemia vera.
FDA Grants Bexmarilimab Orphan Drug Designation for MDS
The investigational immunotherapy bexmarilimab has been granted orphan drug designation from the FDA for patients with myelodysplastic syndromes.
How AI is Revolutionizing MDS Diagnosis
Palak Dave discusses the potential role of artificial intelligence in improving the accuracy of myelodysplastic syndromes diagnosis.
Rusfertide Shows Superior Efficacy in Phase 3 Polycythemia Vera Trial
Rusfertide outperformed placebo in polycythemia vera, meeting all primary and secondary end points in the phase 3 VERIFY study.
First Patient Dosed in Study of Iadademstat Combo in MDS
The first patient with myelodysplastic syndrome has received iadademstat plus azacitidine in a phase 1 trial at the Medical College of Wisconsin.
Exploring Fedratinib in Rare Myeloid Neoplasms
Andrew Kuykendall, MD, discusses the background, methods, and design of a phase 2 study which evaluated fedratinib.
Fedratinib Shows Safety, Potential as Post-Transplant Therapy in MPNs
Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.
Yang Highlights Positive COMMANDS Trial Data for Luspatercept in MDS
During a Case-Based Roundtable® event, Jay Yang, MD, discussed the trial comparing luspatercept with ESA in myelodysplastic syndrome.